FDA19 Mar 2026·FDA Press Release● 6/10i FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
U.S. Food and Drug Administration (FDA)
FDA approved a higher dose of Wegovy (semaglutide 7.2 mg) for weight loss and long-term weight maintenance in adults on March 19, 2026. This represents a label expansion for the existing obesity indication, building on Wegovy's current 2.4 mg weekly injection. Novo Nordisk gains a potential differentiation tool in the competitive obesity market, where Eli Lilly's Zepbound already offers dual-mechanism action. The approval marks the fourth product under FDA's National Priority Voucher Program.
Strategic signal
Novo Nordisk can now position dose escalation as a clinical option for Wegovy partial responders, potentially extending patient persistence versus switching to Zepbound. This mirrors the diabetes market playbook where tirzepatide's superior efficacy drove share gains despite Ozempic's first-mover advantage. US commercial teams will likely target endocrinologists and obesity specialists first, where dose optimization conversations already occur with GLP-1 experienced patients.
Original Abstract
FDA action: Press release | Title: FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide | Date: 2026-03-19 | Geography: United States (FDA) | Details: The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.